HCG Q2 revenue grows 16% to Rs 732 cr
HCG Q2 consolidated revenue rose 16% YoY to Rs 731.8 crore on higher patient volumes, ARPP gains and improved margins; non-institutional share hit 69%.
HCG Q2 revenue grows 16% to Rs 732 crTimes News NetworkBengaluruCancer care specialist HealthCare Global Enterprises (HCG) reported a 16% year-on-year increase in consolidated revenue to Rs 731.8 crore for the September quarter, driven by higher patient volumes and improved revenue per patient.Patient volumes increased 9% year-on-year, while average revenue per patient (ARPP) rose 7%, supported by a favourable payer mix and a higher contribution from advanced oncology treatments. Its margins improved to 19.7% from 19.2% in the year-ago quarter.Revenue growth was also supported by a shift towards non-institutional patients, whose contribution to overall revenue increased by 325 basis points year-on-year to 69%.Dr Manish Mattoo, CEO of HCG, said the company was seeing higher contributions from complex oncology treatments and operational efficiencies. “Our strategic emphasis on expanding the non-institutional business continues to enhance the quality of revenue, with its share improving by 325 basis points year-on-year to 69%,” he said.The company’s international business recorded a 54% increase in revenue to Rs 30.2 crore during the quarter, supported by higher patient volumes in radiation and medical oncology.HCG added 25 operational beds during the quarter, including 13 in Kenya, seven in Kolkata and five in Nagpur. This took the total number of beds added during the first half of FY27 to 146.The company also expanded its advanced technology capabilities, operationalising an MR-LINAC adaptive radiation therapy system at its North Bengaluru facility, a linear accelerator (LINAC) in Africa and a cardiac robotic surgery system at HMS Ahmedabad.Dr B S Ajaikumar, founder and non-executive chairman of HCG, said the company was strengthening its research capabilities in areas such as multi-omics, organoid technology, cellular therapies, including CAR-T, and longevity research.“Our endeavour is to bridge the gap between research and clinical practice, enabling us to better understand the biology of cancer, develop innovative treatment approaches and continually improve patient outcomes,” he said.You use AI every day. Now get your AI Quotient. Take the AIQ test.
Topics in this story
Gathered from external sources. Rights to this text belong to whoever originally published it.